Synageva BioPharmaâ„¢ Highlights Sebelipase Alfa and LAL Deficiency Data at the Lysosomal Disease Network (LDN) WORLD Symposiumâ„¢

[Business Wire] – Synageva BioPharma Corp. , a biopharmaceutical company developing therapeutic products for rare diseases, today announced sebelipase alfa and lysosomal acid more

View todays social media effects on GEVA

View the latest stocks trending across Twitter. Click to view dashboard

See who Synageva is hiring next, click here to view